Drug Profile


Alternative Names: BDP/FF/GB; Beclometasone dipropionate/formoterol fumarate/glycopyrrolate bromide; Beclometasone/glycopyrrolate/formoterol; CHF 5993 pMDI; CHF-5993; Trimbow

Latest Information Update: 25 May 2017

Price : $50

At a glance

  • Originator Chiesi Farmaceutici
  • Class Antiasthmatics; Bronchodilators; Chlorinated steroids; Ethanolamines; Pregnadienetriols; Pyrrolidines; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Immunosuppressants; Muscarinic receptor antagonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Chronic obstructive pulmonary disease
  • Phase III Asthma

Most Recent Events

  • 20 May 2017 Committee for Medicinal Products for Human Use (CHMP) recommends approval of beclometasone/formoterol/glycopyrrolate for chronic obstructive pulmonary disease in Europe
  • 01 Jan 2017 Chiesi Farmaceutici completes the phase III Tristar trial in Chronic obstructive pulmonary disease in Lithuania, Sweden, United Kingdom, Netherlands, Hungary, Germany, Belgium and Poland (Inhalation) (EudraCT2014-001487-35)
  • 01 Nov 2016 Chiesi Farmaceutici plans a phase I trial for Asthma and Chronic obstructive pulmonary disease in United Kingdom (Inhalation) (NCT02975843)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top